HIV-1 genotypic drug resistance testing: Digging deep, reaching wide?

Current Opinion in Virology

Volumn 14, Issue , 2015, Pages 16-23

  Van Laethem, Kristel ^a,b   Theys, Kristof ^a   Vandamme, Anne Mieke ^a,c  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; GENE MUTATION; GENOTYPE; GOLD STANDARD; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NEXT GENERATION SEQUENCING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; DRUG EFFECTS; DRUG MONITORING; GENETICS; GENOTYPING TECHNIQUE; MICROBIAL SENSITIVITY TEST; PROCEDURES;

DRUG MONITORING; DRUG RESISTANCE, VIRAL; GENOTYPE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV-1; MICROBIAL SENSITIVITY TESTS;

EID: 84934909975     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2015.06.001     Document Type: Review

References (69)

1. R. Paredes, and B. Clotet Clinical management of HIV-1 resistance Antiviral Res 85 2010 245 265
2. E. Domingo, J. Sheldon, and C. Perales Viral quasispecies evolution Microbiol Mol Biol Rev 76 2012 159 216
3. A.M. Vandamme, R.J. Camacho, F. Ceccherini-Silberstein, A. de Luca, L. Palmisano, D. Paraskevis, R. Paredes, M. Poljak, J.C. Schmit, and V. Soriano European recommendations for the clinical use of HIV drug resistance testing: 2011 update AIDS Rev 13 2011 77 108
4. D. Frentz, C.A. Boucher, M. Assel, A. De Luca, M. Fabbiani, F. Incardona, P. Libin, N. Manca, V. Müller, and O.B. Nualláin Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time PLoS One 5 2010 e11505
5. C.F. Gilks, S. Crowley, R. Ekpini, S. Gove, J. Perriens, Y. Souteyrand, D. Sutherland, M. Vitoria, T. Guerma, and K. De Cock The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings Lancet 368 2006 505 510
6. K. Van Laethem, K. Van Vaerenbergh, J.C. Schmit, S. Sprecher, P. Hermans, V. De Vroey, R. Schuurman, T. Harrer, M. Witvrouw, and E. Van Wijngaerden Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations J Acquir Immune Defic Syndr 22 1999 107 118
7. N. Koch, N. Yahi, P. Colson, J. Fantini, and C. Tamalet Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis J Virol Methods 80 1999 25 31
8. M.E. Quiñones-Mateu, S. Avila, G. Reyes-Teran, and M.A. Martinez Deep sequencing: becoming a critical tool in clinical virology J Clin Virol 61 2014 9 19
9. D.M. Dudley, E.N. Chin, B.N. Bimber, S.S. Sanabani, L.F. Tarosso, P.R. Costa, M.M. Sauer, E.G. Kallas, and D.H. O'Connor Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance PLoS One 7 2012 e36494
10. B. Vrancken, S. Lequime, K. Theys, and P. Lemey Covering all bases in HIV research: unveiling a hidden world of viral evolution AIDS Rev 12 2010 89 102
11. N. Beerenwinkel, H.F. Günthard, V. Roth, and K.J. Metzner Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data Front Microbiol 3 2012 329
12. A. De Luca, D. Dunn, M. Zazzi, R. Camacho, C. Torti, I. Fanti, R. Kaiser, A. Sönnerborg, F.M. Codoñer, and K. Van Laethem Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe J Infect Dis 207 2013 1216 1220
13. Q.D. Pham, D.P. Wilson, M.G. Law, A.D. Kelleher, and L. Zhang Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis AIDS 28 2014 2751 2762
14. W.L. Yang, R. Kouyos, A.U. Scherrer, J. Böni, C. Shah, S. Yerly, T. Klimkait, V. Aubert, H. Furrer, and M. Battegay Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012 J Infect Dis 212 2015 28 38
15. R.K. Gupta, M.R. Jordan, B.J. Sultan, A. Hill, D.H. Davis, J. Gregson, A.W. Sawyer, R.L. Hamers, N. Ndembi, D. Pillay, and S. Bertagnolio Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis Lancet 380 2012 1250 1258
16. D. Ssemwanga, R.W. Lihana, C. Ugoji, A. Abimiku, J. Nkengasong, P. Dakum, and N. Ndembi Update on HIV-1 acquired and transmitted drug resistance in Africa AIDS Rev 17 2015 3 20
17. S. Megens, and K. Van Laethem HIV-1 genetic variation and drug resistance development Expert Rev Anti Infect Ther 11 2013 1159 1178
18. M.A. Wainberg, and B.G. Brenner The impact of HIV genetic polymorphisms and subtype differences on the occurrence of resistance to antiretroviral drugs Mol Biol Int 2012 2012 256982
19. Y. Alemán, L. Vinken, V. Kourí, L. Pérez, A. Álvarez, Y. Abrahantes, C. Fonseca, J. Pérez, C. Correa, and Y. Soto Performance of an in-house human immunodeficiency virus type 1 genotyping system for assessment of drug resistance in Cuba PLoS One 10 2015 e0117176
20. K. Van Laethem, Y. Schrooten, P. Lemey, E. Van Wijngaerden, S. De Wit, M. Van Ranst, and A.M. Vandamme A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene J Virol Methods 123 2005 25 34
21. K. Van Laethem, Y. Schrooten, S. Dedecker, L. Van Heeswijck, K. Deforche, E. Van Wijngaerden, M. Van Ranst, and A.M. Vandamme A genotypic assay for the amplification and sequencing of gag and protease from diverse human immunodeficiency virus type 1 group M subtypes J Virol Methods 132 2006 181 186
22. J.H. Brehm, D.L. Koontz, C.L. Wallis, K.A. Shutt, I. Sanne, R. Wood, J.A. McIntyre, W.S. Stevens, N. Sluis-Cremer, and J.W. Mellors CIPRA-SA Project 1 Study Team: frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors Clin Infect Dis 55 2012 737 745
23. A. Thielen, N. Sichtig, R. Kaiser, J. Lam, P.R. Harrigan, and T. Lengauer Improved prediction of HIV-1 coreceptor usage with sequence information from the second hypervariable loop of gp120 J Infect Dis 202 2010 1435 1443
24. A. Fun, A.M. Wensing, J. Verheyen, and M. Nijhuis Human immunodeficiency virus gag and protease: partners in resistance Retrovirology 9 2012 63
25. S.A. Rabi, G.M. Laird, C.M. Durand, S. Laskey, L. Shan, J.R. Bailey, S. Chioma, R.D. Moore, and R.F. Siliciano Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance J Clin Invest 123 2013 3848 3860
26. K.A. Sutherland, J. Ghosn, J. Gregson, J.L. Mbisa, M.L. Chaix, I. Cohen Codar, J.F. Delfraissy, C. Delaugerre, and R.K. Gupta HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir J Antimicrob Chemother 70 2015 243 248
27. X.M. Zhang, H. Wu, Q. Zhang, T.C. Lau, H. Chu, Z.W. Chen, D.Y. Jin, and B.J. Zheng A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08-BC subtype confers cross-resistance to NNRTIs J Antimicrob Chemother 70 2015 1381 1390
28. A. Gall, B. Ferns, C. Morris, S. Watson, M. Cotten, M. Robinson, N. Berry, D. Pillay, and P. Kellam Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes J Clin Microbiol 50 2012 3838 3844
29. D.M. Dudley, A.L. Bailey, S.H. Mehta, A.L. Hughes, G.D. Kirk, R.P. Westergaard, and D.H. O'Connor Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq Retrovirology 11 2014 122
30. B. Avidor, S. Girshengorn, N. Matus, H. Talio, S. Achsanov, I. Zeldis, I.S. Fratty, E. Katchman, T. Brosh-Nissimov, and D. Hassin Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory J Clin Microbiol 51 2013 880 886
31. R.M. Gibson, A.M. Meyer, D. Winner, J. Archer, F. Feyertag, E. Ruiz-Mateos, M. Leal, D.L. Robertson, C.L. Schmotzer, and M.E. Quiñones-Mateu Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism Antimicrob Agents Chemother 58 2014 2167 2185
32. D.J. Knapp, R.A. McGovern, A.F. Poon, X. Zhong, D. Chan, L.C. Swenson, W. Dong, and P.R. Harrigan "Deep" sequencing accuracy and reproducibility using Roche/454 technology for inferring co-receptor usage in HIV-1 PLoS One 9 2014 e99508
33. B.B. Simen, M.S. Braverman, I. Abbate, J. Aerssens, Y. Bidet, O. Bouchez, C. Gabriel, J. Izopet, H.H. Kessler, and E. Stelzl An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing J Virol Methods 204 2014 31 37
34. S. Gianella, and D.D. Richman Minority variants of drug-resistant HIV J Infect Dis 202 2010 657 666
35. G. Zhang, F. Cai, Z. Zhou, J. DeVos, N. Wagar, K. Diallo, I. Zulu, N. Wadonda-Kabondo, J.S. Stringer, and P.J. Weidle Simultaneous detection of major drug resistance mutations in the protease and reverse transcriptase genes for HIV-1 subtype C by use of a multiplex allele-specific assay J Clin Microbiol 51 2013 3666 3674
36. E.K. Halvas, G.M. Aldrovandi, P. Balfe, I.A. Beck, V.F. Boltz, J.M. Coffin, L.M. Frenkel, J.D. Hazelwood, V.A. Johnson, and M. Kearney Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency J Clin Microbiol 44 2006 2612 2614
37. I.A. Beck, C. Crowell, R. Kittoe, H. Bredell, M. Machaba, C. Willamson, W. Janssens, S. Jallow, G. van der Groen, and Y. Shao Optimization of the oligonucleotide ligation assay, a rapid and inexpensive test for detection of HIV-1 drug resistance mutations, for non-North American variants J Acquir Immune Defic Syndr 48 2008 418 427
38. V.F. Boltz, F. Maldarelli, N. Martinson, L. Morris, J.A. McIntyre, G. Gray, M.J. Hopley, T. Kimura, D.L. Mayers, and P. Robinson Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design J Virol Methods 164 2010 122 126
39. J. Mutsvangwa, I.A. Beck, L. Gwanzura, M.T. Manhanzva, L. Stranix-Chibanda, T. Chipato, and L.M. Frenkel Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean human immunodeficiency virus type-1 subtype C J Virol Methods 210 2014 36 39
40. D. Pillay, J. Herbeck, M.S. Cohen, T. de Oliveira, C. Fraser, O. Ratmann, A.L. Brown, P. Kellam, and PANGEA-HIV. Consortium PANGEA-HIV: phylogenetics for generalized epidemics in Africa Lancet Infect Dis 15 2015 259 261
41. J.A. Johnson, J.F. Li, X. Wei, J. Lipscomb, D. Irlbeck, C. Craig, A. Smith, D.E. Bennett, M. Monsour, and P. Sandstrom Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy PLoS Med 5 2008 e158
42. O. Peuchant, R. Thiébaut, S. Capdepont, V. Lavignolle-Aurillac, D. Neau, P. Morlat, F. Dabis, H. Fleury, B. Masquelier, and ANRS CO3 Aquitaine Cohort Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy AIDS 22 2008 1417 1423
43. M. Balduin, M. Oette, M.P. Däumer, D. Hoffmann, H.J. Pfister, and R. Kaiser Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure J Clin Virol 45 2009 34 38
44. M.R. Jakobsen, M. Tolstrup, O.S. Søgaard, L.B. Jørgensen, P.R. Gorry, A. Laursen, and L. Ostergaard Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome Clin Infect Dis 50 2010 566 573
45. J.D. Stekler, G.M. Ellis, J. Carlsson, B. Eilers, S. Holte, J. Maenza, C.E. Stevens, A.C. Collier, and L.M. Frenkel Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection PLoS One 6 2011 e28952
46. F. Nicot, A. Saliou, S. Raymond, K. Sauné, M. Dubois, P. Massip, B. Marchou, P. Delobel, and J. Izopet Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection J Clin Virol 55 2012 107 113
47. M. Nishizawa, J. Hattori, T. Shiino, T. Matano, W. Heneine, J.A. Johnson, and W. Sugiura Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan PLoS One 8 2013 e83150
48. S. Mohamed, G. Penaranda, D. Gonzalez, C. Camus, H. Khiri, R. Boulmé, C. Sayada, P. Philibert, D. Olive, and P. Halfon Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure AIDS 28 2014 1315 1324
49. E. Todesco, C. Rodriguez, L. Morand-Joubert, M. Mercier-Darty, N. Desire, M. Wirden, P.M. Girard, C. Katlama, V. Calvez, and A.G. Marcelin Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing J Antimicrob Chemother 70 2015 1503 1506
50. E.K. Halvas, A. Wiegand, V.F. Boltz, M. Kearney, D. Nissley, M. Wantman, S.M. Hammer, S. Palmer, F. Vaida, J.M. Coffin, and J.W. Mellors Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients J Infect Dis 201 2010 672 680
51. V.F. Boltz, Y. Bao, S. Lockman, E.K. Halvas, M.F. Kearney, J.A. McIntyre, R.T. Schooley, M.D. Hughes, J.M. Coffin, J.W. Mellors, and OCTANE/A5208 Team Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP J Infect Dis 209 2014 703 710
52. T.S. Flys, D. Donnell, A. Mwatha, C. Nakabiito, P. Musoke, F. Mmiro, J.B. Jackson, L.A. Guay, and S.H. Eshleman Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission J Infect Dis 195 2007 711 715
53. P. Delobel, A. Saliou, F. Nicot, M. Dubois, S. Trancart, P. Tangre, J.P. Aboulker, A.M. Taburet, J.M. Molina, and P. Massip Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure PLoS One 6 2011 e21655
54. C. Charpentier, D. Laureillard, C. Piketty, P. Tisserand, D. Batisse, M. Karmochkine, A. Si-Mohamed, and L. Weiss High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors AIDS 24 2010 867 873
55. C. Charpentier, G.Q. Lee, C. Rodriguez, B. Visseaux, A. Storto, C. Fagard, J.M. Molina, C. Katlama, Y. Yazdanpanah, P.R. Harrigan, and D. Descamps Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response J Antimicrob Chemother 2015
56. A.C. Pineda-Peña, Y. Schrooten, L. Vinken, F. Ferreira, G. Li, N.S. Trovão, R. Khouri, I. Derdelinckx, P. De Munter, and C. Kücherer Trends and predictors of transmitted drug resistance (TDR) and clusters with TDR in a local Belgian HIV-1 epidemic PLoS One 9 2014 e101738
57. W.L. Yang, R.D. Kouyos, J. Böni, S. Yerly, T. Klimkait, V. Aubert, A.U. Scherrer, M. Shilaih, T. Hinkley, and C. Petropoulos Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds PLoS Pathog 11 2015 e1004722
58. A.M. Geretti, T. Conibear, A. Hill, J.A. Johnson, L. Tambuyzer, K. Thys, J. Vingerhoets, Y. Van Delft, and SENSE Study Group Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz J Antimicrob Chemother 69 2014 1090 1097
59. L. Wittkop, H.F. Günthard, F. de Wolf, D. Dunn, A. Cozzi-Lepri, A. de Luca, C. Kücherer, N. Obel, V. von Wyl, and B. Masquelier Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study Lancet Infect Dis 11 2011 363 371
60. T.J. Wilkin, M.B. Goetz, R. Leduc, G. Skowron, Z. Su, E.S. Chan, J. Heera, D. Chapman, J. Spritzler, and J.D. Reeves Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity Clin Infect Dis 52 2011 925 928
61. L.C. Swenson, T. Mo, W.W. Dong, X. Zhong, C.K. Woods, M.A. Jensen, A. Thielen, D. Chapman, M. Lewis, and I. James Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients J Infect Dis 203 2011 237 245
62. L.C. Swenson, T. Mo, W.W. Dong, X. Zhong, C.K. Woods, A. Thielen, M.A. Jensen, D.J. Knapp, D. Chapman, and S. Portsmouth Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc Clin Infect Dis 53 2011 732 742
63. J.Z. Li, R. Paredes, H.J. Ribaudo, E.S. Svarovskaia, K.J. Metzner, M.J. Kozal, K.H. Hullsiek, M. Balduin, M.R. Jakobsen, and A.M. Geretti Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis JAMA 305 2011 1327 1335
64. A. Cozzi-Lepri, M. Noguera-Julian, F. Di Giallonardo, R. Schuurman, M. Däumer, S. Aitken, F. Ceccherini-Silberstein, A. D'Arminio Monforte, A.M. Geretti, and C.L. Booth Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing J Antimicrob Chemother 70 2015 930 940
65. C. Pou, M. Noguera-Julian, S. Pérez-Álvarez, F. García, R. Delgado, D. Dalmau, M. Álvarez-Tejado, D. Gonzalez, C. Sayada, and N. Chueca Improved prediction of salvage antiretroviral therapy outcomes using ultrasensitive HIV-1 drug resistance testing Clin Infect Dis 59 2014 578 588
66. K. Van Laethem, A. De Luca, A. Antinori, A. Cingolani, C.F. Perna, and A.M. Vandamme A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients Antivir Ther 7 2002 123 129
67. S.Y. Rhee, T.F. Liu, M. Kiuchi, R. Zioni, R.J. Gifford, S.P. Holmes, and R.W. Shafer Natural variation of HIV-1 group M integrase: implications for a new class of antiviral inhibitors Retrovirology 5 2008 74
68. J. Vingerhoets, L. Rimsky, V. Van Eygen, S. Nijs, S. Vanveggel, K. Boven, and G. Picchio Pre-existing mutations in the rilpivirine phase III trials ECHO and THRIVE: prevalence and impact on virological response Antivir Ther 18 2013 253 256
69. S. Mohamed, G. Penaranda, D. Gonzalez, C. Camus, H. Khiri, R. Boulmé, C. Sayada, P. Philibert, D. Olive, and P. Halfon Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure AIDS 28 2014 1315 1324